CNS has a diverse and expanding pipeline of oncological solutions for GBM

There have been no major additions to the treatment options for newly diagnosed GBM patients since 2005.

Our lead product candidate, Berubicin, is an innovative, first-in-class anthraycline that appears to cross the blood brain barrier and kill tumor cells. Phase 1 clinical trial data demonstrates 44% of patients achieved a clinical response with Berubicin treatment.